# Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

> **NCT03858270** · PHASE3 · UNKNOWN · sponsor: **Wayne State University** · enrollment: 50 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Memantine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03858270
- **Lead sponsor:** Wayne State University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03858270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03858270, "Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03858270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*